Select a Size
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C6H7N3O
CAS Number:
Molecular Weight:
137.14
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
119374
Product Name
Isoniazid, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
SMILES string
NNC(=O)c1ccncc1
InChI key
QRXWMOHMRWLFEY-UHFFFAOYSA-N
grade
pharmaceutical primary standard
agency
EP Reference Standard
API family
isoniazid
manufacturer/tradename
EDQM
mp
171-173 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Looking for similar products? Visit Product Comparison Guide
Related Categories
Application
Isoniazid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
Antibiotic for treatment of Mycobacterium tuberculosis, inhibits mycolic acid biosynthesis. Metabolized by hepatic N-acetyltransferase (NAT) and cytochrome P450 2E1 (CYP2E1) to form hepatotoxins. Selectively induces expression of CYP2E1. Reversibly inhibits CYP2C19 and CYP3A4 activities, and mechanistically inactivates CYP1A2, CYP2A6, CYP2C19 and CYP3A4 at clinically relevant concentrations.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Skin Irrit. 2
Storage Class
11 - Combustible Solids
wgk
WGK 3
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Anandi Martin et al.
The Journal of antimicrobial chemotherapy, 62(1), 56-64 (2008-04-15)
The reference standard methods for drug susceptibility testing (DST) of M. tuberculosis are very slow to give results, and due to the emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis, there is an urgent demand for new, rapid and
Laura Muñoz et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 60(3), 349-356 (2014-10-15)
The extent to which anti-tumor necrosis factor (TNF)-associated tuberculosis can be prevented is unclear, and there is no established guidance on the optimal screening strategy for latent tuberculosis (LTBI) in patients about to start anti-TNF therapy. We aimed to determine
Molebogeng X Rangaka et al.
Lancet (London, England), 384(9944), 682-690 (2014-05-20)
Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid preventive therapy on the risk of tuberculosis in people infected with
A fresh look at the mechanism of isoniazid-induced hepatotoxicity.
I G Metushi et al.
Clinical pharmacology and therapeutics, 89(6), 911-914 (2011-03-18)
Andrew D Kerkhoff et al.
PloS one, 7(11), e49928-e49928 (2012-12-05)
People living with HIV (PLWH) who have positive tuberculin skin tests (TST) benefit from isoniazid preventive therapy (IPT) whereas those testing TST-negative do not. Revised World Health Organization guidelines explicitly state that assessment of TST is not a requirement for
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service